A novel role for endothelial tetrahydrobiopterin in mitochondrial redox balance

Jade Bailey\textsuperscript{a}, Andrew Shaw\textsuperscript{a}, Roman Fischer\textsuperscript{b}, Brent J. Ryan\textsuperscript{c}, Benedikt M. Kessler\textsuperscript{b}, James McCullagh\textsuperscript{d}, Richard Wade-Martins\textsuperscript{e}, Keith M. Channon\textsuperscript{a,⁎}, Mark J. Crabtree\textsuperscript{a}

\textsuperscript{a} BHF Centre of Research Excellence, Division of Cardiovascular Medicine, Radcliffe Department of Medicine, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DU, United Kingdom
\textsuperscript{b} Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Roosevelt Drive, Oxford OX3 7FZ, United Kingdom
\textsuperscript{c} Oxford Parkinson’s Disease Centre, Department of Physiology, Anatomy and Genetics, South Parks Road, Oxford OX1 3QX, United Kingdom
\textsuperscript{d} Department of Chemistry, University of Oxford, South Parks Road, Oxford OX1 3QX, United Kingdom

\textbf{Keywords:}
Tetrahydrobiopterin
Redox state
Nitric oxide synthase
Mitochondria
Superoxide

\textbf{A B S T R A C T}

The redox co-factor tetrahydrobiopterin (BH\textsubscript{4}) regulates nitric oxide (NO) and reactive oxygen species (ROS) production by endothelial NOS (eNOS) and is an important redox-dependent signalling molecule in the endothelium. Loss of endothelial BH\textsubscript{4} is observed in cardiovascular disease (CVD) states and results in decreased NO and increased superoxide (O\textsubscript{2}\textsuperscript{-}) generation via eNOS uncoupling. Genetic mouse models of augmented endothelial BH\textsubscript{4} synthesis have shown proof of concept that endothelial BH\textsubscript{4} can alter CVD pathogenesis. However, clinical trials of BH\textsubscript{4} therapy in vascular disease have been limited by systemic oxidation, highlighting the need to explore the wider roles of BH\textsubscript{4} to find novel therapeutic targets. In this study, we aimed to elucidate the effects of BH\textsubscript{4} deficiency on mitochondrial function and bioenergetics using targeted knockdown of the BH\textsubscript{4} synthetic enzyme, GTP Cyclohydrolase I (GTPCH). Knockdown of GTPCH by > 90\% led to marked loss of cellular BH\textsubscript{4} and a striking induction of O\textsubscript{2}\textsuperscript{-} generation in the mitochondria of murine endothelial cells. This effect was likewise observed in BH\textsubscript{4}-depleted fibroblasts devoid of NOS, indicating a novel NOS-independent role for BH\textsubscript{4} in mitochondrial redox signalling. Moreover, this BH\textsubscript{4}-dependent, mitochondria-derived ROS further oxidised mitochondrial BH\textsubscript{4} concomitant with changes in the thioredoxin and glutathione antioxidant pathways. These changes were accompanied by a modest increase in mitochondrial size, mildly attenuated basal respiratory function, and marked changes in the mitochondrial proteome and cellular metabolome, including the accumulation of the TCA intermediate succinate. Taken together, these data reveal a novel NOS-independent role for BH\textsubscript{4} in the regulation of mitochondrial redox signalling and bioenergetic metabolism.

\textbf{1. Introduction}

Tetrahydrobiopterin (BH\textsubscript{4}) is a redox-active cofactor and has long been known to be a critical regulator of nitric oxide synthase (NOS) coupling and the production of nitric oxide (NO) [1,2]. Loss of endothelial BH\textsubscript{4}, via decreased synthesis or oxidation to 7,8-dihydrobiopterin (BH\textsubscript{4}), is associated with endothelial NOS (eNOS) uncoupling, whereby the superoxide radical (O\textsubscript{2}\textsuperscript{-}), rather than NO, is produced [3,4]. Moreover, the reaction of O\textsubscript{2}\textsuperscript{-} and NO forms peroxynitrite (ONOO\textsuperscript{-}), leading to further loss of NO and increased uncoupling due to BH\textsubscript{4} oxidation, thereby profoundly altering the balance between production of NO and reactive species (termed NO-redox balance) and associated signalling pathways [5–7]. The cellular NO-redox state is fundamental to the maintenance of vascular homeostasis and uncoupled eNOS is strongly associated with the development and progression of cardiovascular vascular disease (CVD) [8]. However, BH\textsubscript{4} also has other cofactor and antioxidant roles, throughout a wide range of biological processes and pathological states, including phenylalanine catabolism, synthesis of neurotransmitters, and ether lipid metabolism [8]. Furthermore, BH\textsubscript{4} has other important roles in cellular redox-sensitive signalling pathways [9,10].

GTP cyclohydrolase I (GTPCH), encoded by Gch1, is the primary rate-limiting enzyme involved in the synthesis of BH\textsubscript{4}. Targeted augmentation of Gch1 expression in endothelial cells has proven sufficient to normalise endothelial function, eNOS coupling, and reactive oxygen species (ROS) production in models of diabetes and atherosclerosis [11–13]. Similarly, targeted knockout of Gch1 in endothelial cells has led to elevated blood pressure in mouse models...
in vivo [14]. However, clinical trials of BH₄ therapy in vascular disease have been limited by systemic oxidation and limited endothelial uptake of BH₄, highlighting the need explore the wider roles of BH₄ in order to identify novel therapeutic targets.

Redox signalling is the specific, usually reversible, reduction/oxidation modification of signalling pathway components by reactive oxygen species.
species and is increasingly acknowledged to be of central importance to many physiological and pathophysiological processes. Increased production of ROS is associated with a variety of disease states such as cancer [15], Parkinson’s [16], and cardiovascular disease [17]. Indeed, the NO-redox balance is crucial to the maintenance of cellular homeostasis and perturbations to this balance have far-reaching effects [8]. Whilst the consequences of uncoupled NOS on O2 have been described [18], the effects of BH4 deficiency on other redox pathways remain unknown. Mitochondria are major sources of cellular ROS, via the production of O2 at various sites along the electron transport chain, and present ideal targets for therapeutic intervention. However, therapeutic strategies to alleviate ROS production, such as through the administration of antioxidants, have proved largely unsuccessful and closer investigation of the signalling mechanisms and the loci-dependent effects of ROS production is required in order to therapeutically target specific pathways. We have previously shown that decreased levels of endothelial BH4 in both cell culture and animal models leads to increased cellular generation of O2 and that a proportion of this superoxide is produced directly from uncoupled eNOS [10]. Although our previous studies have focused on this eNOS-derived fraction of cellular O2 production in response to deficient levels of BH4, the major source of the increased superoxide levels has so far remained unexplored. The aim of the current study was to explore the impact of BH4 deficiency on redox signalling using siRNA-knockdown of the BH4 synthetic enzyme GTPCH in murine endothelial cells.

**Fig. 1.** Model of endothelial BH4 deficiency through knock down of GTPCH leads to increased mitochondrial superoxide production. sEnd.1 murine endothelial cells were transfected with an siRNA pool targeted to Gch1 (siRNA) or a non-targeting (NS) scrambled control siRNA. The cells were then harvested and analysed for GTPCH protein expression by Western blotting, or biopterin levels using HPLC with electrochemical and fluorescent detection. A) Western blot analysis shows that cellular GTPCH protein was diminished by over 90% following exposure to Gch1-specific siRNA, compared to untreated cells, non-specific (NS) siRNA, and DNA only transfected control cells. B) Gch1-specific siRNA significantly decreased the detectable levels of cellular biopterins and C) the ratio of BH4 to BH2 + B, and D) increased the proportion of oxidised biopterins compared with NS siRNA controls. E) Gch1 siRNA lead to significantly decreased NO activity and D) NOx accumulation using a NO Analyser. n =3 (**p < 0.05, **p < 0.01). A combination of methods was used to elucidate the source of superoxide induced by modified redox state in response to BH4 deficiency. G) sEnd.1 endothelial cells were transfected with Gch1-specific and control siRNA, incubated for 72 h and then exposed to MitoSOX™ Red, MitoTracker® Green, or Hoechst nuclear stain or dihydroethidium (DHE). Confocal microscopy shows an increase in mitochondria-derived superoxide from BH4-deficient cells exhibited by increased MitoSOX™ fluorescence and MitoTracker® Green co-localisation. H) Quantitative measurements were obtained following exposure of these GCH-specific and NS control cells to dihydroethidium. The specific product, 2-hydroxyethidium, was measured by HPLC as outlined in the Experimental Procedures; increased accumulation of 2-hydroxyethidium, indicative of superoxide formation, was observed in cells with diminished levels of BH4. This signal was attenuated by pre-treatment with MitoTEMPO. I) MitoTEMPO also partially restored the attenuated BH4:BH2+B ratio following transfection of Gch1-specific siRNA. n =4 (**, p < 0.05) (**, p < 0.01) (i, p < 0.05).

**Fig. 2.** Elevated superoxide production is attenuated by rotenone, or supplementation with sepiapterin. Gch1-specific siRNA and NS treated control were incubated with DHE, and the accumulation of 2-hydroxyethidium was measured by HPLC with fluorescent detection. A) Pre-treatment of cells with L-NAME (200 μM/litre), apocynin (100 μM/litre), oxyapurinol (100 μM/litre), rotenone (2 μM/litre) or TIFA (5 μM/litre) reveals a significant attenuation of superoxide in BH4 deficient Gch1-siRNA cells treated with L-NAME (**p < 0.05) or rotenone (***, p < 0.001), compared to control cells. B) Similarly, GCH-tet cells demonstrate decreased 2-hydroxyethidium accumulation compared to TET cells that do not express GCH (***p < 0.001). The increase in superoxide levels in GCH-tet cells following 10 days exposure to doxycycline is also significantly reduced by rotenone treatment (**p < 0.01). C and D) Treatment of Gch1-siRNA and GCH-tet cells with sepiapterin restored BH4 levels to at least basal levels, and E and F) abolished the superoxide production that was elevated by BH4 depletion. n =4/6 (*, p < 0.05) (**, p < 0.001).
2. Results

2.1. Characterisation of Gch1 knockdown-induced BH4 deficiency

We first tested the effect of targeting Gch1 gene expression, through RNA interference, on the knockdown of GTPCH protein and subsequent effects on cellular BH4 levels. Transfection of sEnd.1 cells with Gch1-specific siRNA lead to a substantial decrease in GTPCH protein, as detected by Western blotting (Fig. 1A). The depletion of GTPCH was paralleled by a ~80% decrease in cellular BH4 levels (Fig. 1B). The alteration of eNOS:BH4 ratio (previously demonstrated by our laboratory [18]), by depletion of BH4, also lead to a significantly decreased ratio of BH4 relative to oxidised biopterin species (BH4:BH2+B) and a 2-fold increase in the accumulation of oxidised biopterins in Gch1-knockdown vs. NS control cells (Fig. 1C and D). BH4 depletion was also sufficient to significantly lower eNOS activity and NOx accumulation (Fig. 1E and F).

2.2. BH4-dependent alterations in cellular NO:redox balance determine mitochondrial redox state

Subsequent to the observation that GTPCH knockdown led to the oxidation of intracellular BH4, the origin of this oxidative stress was investigated using microscopic and analytical techniques. Confocal imaging of BH4-deficient sEnd.1 cells treated with MitoSOX™ Red demonstrated a substantial increase in mitochondrial O2−, which co-localised with the mitochondrial probe MitoTracker® Green (Fig. 1G).

For quantification, we used HPLC to measure the accumulation of 2-hydroxyethidium in cells incubated with dihydroethidium, as an indicator of O2− production. Gch1 knockdown and GTPCH depletion resulted in a marked increase in measurable 2-hydroxyethidium (Fig. 1H) with consequent accumulation of BH2 and decrease in BH4:BH2 ratio (Fig. 1I). Moreover, increased ROS generation, and the subsequent effects on BH4:BH2 ratio, were both prevented by the mitochondrial-targeted antioxidant MitoTEMPO (Fig. 1H and I).

To further identify the source of BH4-dependent ROS production, we systematically inhibited enzyme systems known to generate O2−. Selective inhibition of NADPH oxidase (by apocynin), xanthine oxidase (by oxypurinol) and mitochondrial complex II (by TTFA), had no effect on superoxide production, whilst the NOS inhibitor L-NAME resulted in only a partial decrease in O2− levels (Fig. 2A). However, rotenone (an inhibitor of mitochondrial complex I) had a striking inhibitory effect that normalised the levels of O2− in BH4-depleted sEnd.1 cells to that of control cells (Fig. 2A). This rotenone-inhibitable portion of detectable O2− was 2.5-fold greater than that which was attenuated using L-NNAME (inset, i and ii). This rotenone-dependent inhibition was equally apparent in BH4-deficient (non-eNOS expressing) GCH cells exposed to doxycycline (Fig. 2B). Furthermore, supplementation of both siRNA and Tet-OFF models with sepiapterin restored BH4 levels (Fig. 2C and D) and diminished levels of O2− to those of control cells (Fig. 2E and F).

The effect of BH4 deficiency on the redox balance of isolated mitochondria was investigated. Mitochondrial preparations were as-
Assessed by Western blotting; anti-succinate dehydrogenase (SDH), -voltage-dependent anion channel (VDAC), and -cytochrome C antibodies confirmed mitochondrial enrichment, without cytosolic GAPDH contamination (Fig. 3A). The total amount of bioproteins detected in mitochondria from sEnd.1 endothelial cells was 3-fold lower in Gch1-specific siRNA-treated cells (49.7 ± 13.6 vs 145.5 ± 28.7 pmol/mg protein), compared to mitochondria isolated from non-specific siRNA-treated control cells. Mitochondria from BH4-replete control cells contained 85.6 ± 19.5 pmol/mg protein of BH4 vs. 26.0 ± 8.0 pmol/mg protein in Gch1-siRNA cells, and 53.6 ± 8.3 vs 19.5 ± 4.3 pmol/mg protein of BH2 (Fig. 3B). These data imply an oxidising mitochondrial environment, as the BH4:BH2 ratio is much lower in the mitochondria compared to that in whole cells (29.3 ± 11.3 in whole cells vs 1.4 ± 0.14 in mitochondria). The lower mitochondrial BH4:BH2 ratio was even more perturbed by the changes in redox balance induced by diminished BH4 levels—the ratio of BH2:BH4 being significantly decreased in mitochondria from Gch1-specific siRNA-treated cells versus non-specific controls (1.04 ± 0.11 vs 1.4 ± 0.14), with the relative amount of oxidised bioproteins increasing (Fig. 3C and D; *P < 0.05).

2.3. Diminished BH4 levels and subsequent alterations in redox state alter mitochondrial size and function

To examine further the impact of BH4 depletion on mitochondrial function, mitochondrial respiration, morphology, and protein composition were investigated. Mitochondrial OCR was assessed under basal conditions, followed by consecutive measurements after exposure to oligomycin, Carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP), and antimycin A/rotenone compounds that variously inhibit respiratory capacity, proton leak, or ATP linked respiration (data not shown).

Fig. 4. Altered mitochondrial redox state induces changes in mitochondrial structure and function. A and B) The observed changes in mitochondrial redox state also altered mitochondrial bioenergetics, as shown by the significant decrease in basal oxygen consumption rates (OCR) in Gch1-specific siRNA transfected cells compared to their NS treated control cells. OCR was measured using an XFe96 extracellular flux assay. OCR measurements were taken at baseline and then following sequential injections of oligomycin, FCCP and rotenone + antimycin A OCR was significantly decrease in siRNA treated (red) cells at baseline (vs control, blue). Analysis of electron micrographs from C) NS control cells, and D) Gch1 siRNA transfected cells reveals that cellular mitochondria exhibit E) a trend towards increased area, F) and a significant increase in length, G) independent of a difference in absolute number (averages from NS =11 cells, Gch1 = 12 cells). H) Evidence for increased mitochondrial size and mitochondrial fusion was supported by Western blot analysis; TOM20 and COXVI increased in Gch1 siRNA cells compared to NS control cells. I) Further Western blotting demonstrates a striking decrease in p(616)Drp1, but not p(637)Drp1, with no difference in mitofusin 2 or OPA1. M and N) No change in the quantity of mtDNA was observed between GCH siRNA and control cells. All data represents 6-8 independent experiments (*, p < 0.05). n = 4-5 for Western blots.

Treatment of endothelial cells with Gch1-specific siRNA, and the subsequent BH4 deficiency, resulted in modest changes in mitochondrial size (measured by electron microscopy, shown in Fig. 4C and D) and levels of certain important proteins relating to mitochondrial content/dynamics. Mitochondria from BH4-deficient endothelial cells showed increased length and area compared to control, in the absence of any change in absolute mitochondrial number (Figs. 4E-G; *P < 0.05). Western blots also supported evidence of an increase in mitochondrial size, with TOM20 and COXIV (inner and outer membrane markers, respectively) increased in BH4-deficient mitochondria (Fig. 4H). Furthermore, the phosphorylation status of the master fission regulatory protein, dynamin related protein-1 (DRP1) was significantly decreased at the activating phosphorylation site, serine 616 (Fig. 4I) without concurrent changes at the inhibitory site of serine 637 (Fig. 4K). These changes were independent of alterations in the amount of total DRP1 protein (Fig. 4L) in control Gch1 siRNA cells (Fig. 4I). Markers of mitochondrial fusion (OPA1, and Mitofusin 2) (Fig. 4I) and mitochondrial DNA content (Fig. 4M and N) showed no difference...
Fig. 5. Modulation of the mitochondrial proteome by BH4. Gch1 siRNA and control cells underwent proteomic analysis by mass spectrometry. A) Normalised relative abundance of detected proteins was determined as described in the 'Experimental Procedures' (data shown in Supplemental Tables 1 and 2), and significant changes in 46 proteins presented in the heat map. Data presented represent 46 candidate proteins, changed by over 1.5-fold and 1% false discovery rate. Proteins were ranked by fold difference between Gch1 siRNA and NS expressing cells. Higher abundant proteins are expressed in Red, and those of lower abundance, compared to the average of all values, are shown in Blue. B) Ingenuity Pathway Analysis was used to highlight which pathways were experimentally modulated by BH4 in our cell model. Thioredoxin (downregulated) and glutathione (upregulated) antioxidant systems were found to be down altered in BH4 deficient cells, as well as several proteins from the 'Oxidative Phosphorylation' pathway identified by IPA. C) These proteomic data were confirmed by Western blot analysis, and those 'hits' shown to be modified in abundance to the largest extent were validated using specific antibodies. TXNIP, TRX and FH were shown to be decreased upon knockdown of Gch1, and GR and VDAC were demonstrated to be significantly elevated. D) Densitometric analysis of Western blot bands.

Fig. 6. Metabolomic analysis reveals a role for BH4 in metabolism. sEnd.1 endothelial cells were transfected with Gch1-specific siRNA and compared to cells transfected with NS scrambled control siRNA. Cell lysates were harvested and underwent metabolomics analysis as outlined in the 'Experimental Procedures'. A) Glycolysis (red) and TCA cycle (blue) metabolites were detected and quantification established by comparison with known standards. Succinate, fumarate, phosphoenolpyruvate and Fructose 1,6-bisphosphate were significantly increased in response to Gch1-specific siRNA transfection, while isocitrate levels were shown to be markedly diminished compared to NS control cells. B) The impact of these changes in mitochondrial electron transport chain protein expression, glycolytic and TCA cycle metabolites, was to significantly decrease ATP/ADP ratio induced following knockdown of Gch1 by targeted siRNA, and the resulting BH4 deficiency. n = 3 (*, p < 0.05) (**, p < 0.01) (***, p < 0.001).
between control and Gch1-specific siRNA treatments, as measured by Western blotting (Supplementary Fig. 2).

### 2.4. BH4 is a redox-dependent modulator of mitochondrial signalling

The effects of BH4-dependent perturbations in mitochondrial redox balance on both the mitochondrial proteome and cellular metabolome were in investigated using mass spectrometry. Analysis of the mitochondrial proteome showed that BH4 deficiency resulted in proteome remodelling, as illustrated by the heat map in Fig. 5A. BH4 deficiency led to profound changes in the abundance of proteins involved with mitochondrial dynamics redox signalling, and bioenergetic metabolism. For example, proteins with the most significantly altered response to reduced levels of BH4 and subsequent altered redox homeostasis included those involved in antioxidant signalling mechanisms; thioredoxin (TRX) and thioredoxin-interacting protein (TXNIP) both decreased in abundance in Gch1-specific siRNA endothelial cells vs control cells, whilst glutathione reductase (GR) and glutaredoxin-2 (GRX2) were both increased. Metabolic proteins fumarate hydratase and isocitrate dehydrogenase also significantly decreased in response to BH4 deficiency. Moreover, mitochondrial import proteins (TOM20, TIM10, TIM13 and TIM23) were upregulated (Fig. 5A). The roles and impact of these changes are outlined in the discussion. Ingenuity Pathway Analysis (IPA) then identified downstream pathways modified in sEnd1 endothelial cells following knockdown of Gch1 and revealed oxidative phosphorylation, thioredoxin, and glutathione as affected pathways (Fig. 5B). These data were confirmed by Western blot analysis, which also showed TXNIP, TRX, and fumarate hydratase to be decreased, while the abundance of GR was increased in Gch1-specific siRNA vs. non-specific siRNA treated endothelial cells (Fig. 5C and D). These changes were dependent on both cellular BH4 and mitochondria-derived ROS, as demonstrated by Western blotting; the decrease in TRX protein expression (a candidate protein selected from our proteomics data) was prevented following inhibition of mito-ROS by MitoTEMPO and after supplementation of intracellular BH4 using sepiapterin (Fig. 5E and F). The impact of these changes could also be observed at the cellular metabolite level; levels of succinate (\( *P < 0.01 \)) and fumarate (\( *P < 0.05 \)) were markedly decreased, whilst isocitrate was increased in Gch1-specific siRNA vs. non-specific siRNA treated endothelial cells (\( *P < 0.05 \); Fig. 6A). Similarly, the level of fructose 1,6-bisphosphate was strikingly elevated (3-fold) in BH4-deficient endothelial cells, compared to control siRNA treated cells (\( **P < 0.01 \)). The overall effect of these changes on cellular energy levels was a modest, but significant, decrease of the ATP/ADP ratio in BH4-deficient cells (Fig. 6B).

### 3. Discussion

In this study, we investigated BH4-dependent mitochondrial redox signalling using both siRNA knockdown of Gch1 in endothelial cells, and tetracycline-regulatable GCH1 fibroblast ("GCH") cell-culture models of BH4 deficiency. Gch1 knockdown and consequent BH4 deficiency had profound effects on mitochondria-derived O2\(_\text{2}^-\) and the mitochondrial proteome, whilst also affecting levels of several important cellular bioenergetic metabolites. These findings paralleled modest, yet consistent, changes in mitochondrial size and basal respiration, together suggesting a critical role for BH4 deficiency in mitochondrial redox signalling and homeostasis.

Whilst we have previously described the effects of BH4 deficiency on eNOS uncoupling-dependent O2\(_\text{2}^-\) generation in Tet-regulated GCH/ eNOS and sEnd1 endothelial cells [19], the present study highlights an important fraction of the increased O2\(_\text{2}^-\) production due to BH4 deficiency that is not inhibited by treatment with L-NAME, suggesting an eNOS-independent source. Moreover, this increase in O2\(_\text{2}^-\) production in BH4-deficient cells was normalised by either scavenging with MitoTEMPO, restoration of BH4 levels, or the pharmacological inhibition of mitochondrial complex I in both siRNA and Tet cell models, together implicating an eNOS-independent component of increased O2\(_\text{2}^-\) production that is specifically mitochondrial in origin. Additionally, O2\(_\text{2}^-\) production was also visibly localised to the mitochondria when imaged after incubation with DHE, thus further substantiating the finding. Whilst it is likely that O2\(_\text{2}^-\) derived from uncoupled eNOS can induce further ROS generation via a feed-forward mechanism [20], data from the GCH model (which inherently lacks NOS) corroborate the notion of an eNOS-independent mechanism linking BH4 deficiency and mitochondrial O2\(_\text{2}^-\) overproduction. However, the specific role of BH4 within the mitochondria is yet to be elucidated and complicated by uncertainties regarding the presence or absence of mitochondria-specific NOS. Recently, Sethumadhavan et al. [21] showed that increasing BH4 in cardiomyocytes affected redox state and mitochondrial function independent of differences in NO generation. This finding further supports our hypothesis of an NOS-independent role for BH4 in the mitochondria, albeit in model overexpressing GTPCH many fold. Notwithstanding the magnitude of this overexpression, there appears to be mounting evidence for an alternate role for BH4 in the mitochondria, beyond its canonical function in NOS coupling. However, to our knowledge, our study is the first report of an eNOS-independent role for BH4 in the excess generation of mitochondrial O2\(_\text{2}^-\) and associated redox signalling.

Comitant with BH4 deficiency and increased O2\(_\text{2}^-\) production were decreases in both overall BH4 and the ratio of BH4 to oxidised bioprotein species (BH2+B) in the mitochondria, indicating that genetic manipulation of GTPCH levels has specific effects within the mitochondrial compartment. Whilst both mitochondrial bioproteins and GTPCH localisation have previously been reported [22–24], the concept of GTPCH producing BH4 specifically within the mitochondrial compartment is one that merits more thorough investigation. Similarly, BH4 transport is poorly understood, although it has been suggested that cellular uptake of BH4 possibly occurs via either urate transporters (URAT1), organic anion transporters (OATs), or multidrug-resistance-associated proteins (MRPs) in the kidney [25]. However, the fact that sepiapterin rescues the increased ROS generation induced by BH4 deficiency in the mitochondria suggests that BH4 may be indeed be transported there and further study is required.

That we show at least partial rescue of the cellular ratio of BH4 to oxidised bioproteins, via the addition of the superoxide-scavenging MitoTEMPO, is an indication that mitochondrial O2\(_\text{2}^-\) overproduction may be another important mediator of mitochondrial BH4 bioavailability, suggesting a vicious cycle of events associated with BH4 depletion and ROS overproduction. Whilst we have previously shown that the ratio of BH4 to oxidised bioproteins is more important to eNOS coupling and NO-redox balance than BH4 levels per se [26], it remains...
to be determined whether this is true for any eNOS-independent roles of BH4 in the mitochondria.

We hypothesised that BH4 deficiency and concomitant increase in mitochondrial O$_2^-$ would be associated with altered bioenergetic metabolism and changes in mitochondrial respiration rates. Whilst BH4 depletion was associated only with a small decrease in basal OCR, there were profound changes in certain TCA metabolite levels and the cellular ATP/ADP ratio, suggesting an important bioenergetic component. The modest decrease in basal OCR observed under conditions of BH4 deficiency is suggestive of mild impairment of mitochondrial respiratory function; however, the uncoupled reserve capacity remained unchanged (data not shown), indicating that the overt effect of BH4 deficiency on mitochondrial functional respiratory capacity was limited. However, given the relatively short duration of this in vitro knockdown model (72 h) and the highly adaptive nature of mitochondria to ensure maintenance of functional respiratory capacity, it would be prudent to investigate the effects of long-term BH4 depletion on mitochondrial bioenergetics and oxygen consumption in vivo. Similarly, BH4 depletion was also associated with a modest increase in mitochondria size. Protein analysis by Western blotting suggests this is due to decreased activity of fission machinery, as evidenced by the observation that DRP1 was shown to be less phosphorylated at the activating phosphorylation site of serine 616, without any changes observed in fusion proteins (mitofusin 2 and OPA1). Nevertheless, these modest changes in size and basal oxygen utilisation paralleled profound changes in mitochondrial O$_2^-$ generation and protein import into the mitochondria, which are well equipped to adapt to metabolic stress, thus preserving vital respiratory function.

Our studies also reveal changes in important cellular metabolites that further link mitochondrial bioenergetic metabolism and BH4 deficiency. The accumulation of both succinate and fumarate are an interesting finding that suggests BH4 deficiency has an effect on key mitochondrial metabolites of the TCA cycle. Chouchani et al. [27] proposed that succinate accumulation (resulting from ischaemia) is the major driver of mitochondrial succinate production via complex I. Indeed, it may be prudent to explore the impact of succinate accumulation on mitochondrial superoxide generation in BH4-deficient cells. Furthermore, the stark decrease in isocitrate, and striking increase in fructose 1,6-bisphosphate (possibly as a compensatory protective mechanism against the oxidative insult induced by BH4 deficiency, akin to that observed in ischemic injury [28]) further highlight a profound change in TCA and glycolytic metabolism under conditions of BH4 deficiency. Thus, whilst the link between BH4 deficiency, mitochondrial bioenergetic metabolism, and increased superoxide generation remains unclear, it warrants further investigation. Taken together, these results suggest that BH4 deficiency specifically alters mitochondrial metabolic/bioenergetic homeostasis, in tandem with increased mitochondrial superoxide production in vitro.

We also investigated the effect of BH4 deficiency on the cell proteome and found a dramatically altered profile, which included changes in a wide range of proteins associated with mitochondrial redox signalling, mitochondrial metabolism, antioxidant defence, and stress response. The thioredoxin and glutaredoxin systems are both critical mediators of mitochondrial redox homeostasis [29]. Both TRX and TXNIP were downregulated under conditions of BH4 deficiency, whilst GR and the mitochondrial GRX2 were upregulated, reflecting an altered redox balance due to increased ROS generation. This change in proteins central to major redox signalling/antioxidant pathways was confirmed by Western blot and serves to highlight differential cellular responses to BH4 deficiency, operating via discrete redox signalling pathways. Indeed, the thioredoxin and glutaredoxin systems are important regulators of redox signalling specifically because of their ability to both cooperate and function independently of each other [30]. Moreover, the addition of a mitochondrial superoxide scavenger (MitoTEMPO) and supplementation of BH4 levels using sepiapterin, are both sufficient to rescue the depletion of thioredoxin in BH4-deficient cells. When taken together with the data presented herein that demonstrates the ability of MitoTEMPO and sepiapterin to individually normalise the decrease in BH4, and the increase in ROS in Gch1 siRNA-treated cells, this shows strong evidence that BH4-deficiency, and consequent mitochondrial ROS generation, negatively affect the abundance of these selected cellular enzymatic antioxidants.

Similarly, BH4 deficiency induced changes in various other redox proteins possessing ferroxidase and oxidoreductase activity—such as ferritin light/heavy chains and phosphoglycerate dehydrogenase that were up- and downregulated, respectively—reinforcing the importance of BH4 in redox signalling homeostasis. Further evidence for a redox-regulatory role for BH4 was provided by upstream IPA pathway analysis predicting that Nrf2-dependent signalling may be decreased in response to Gch1 knockdown within endothelial cells (data not shown), supporting our previous findings in primary macrophages isolated from the Gch1$^{fl/fl}$Tie2cre knockout mouse [9].

The mitochondrial import proteins (TOM20, TIM10, TIM13, and TIM23) were all upregulated, suggesting a redox-dependent shift in mitochondrial dynamics [31]. However, mitochondrial fission regulator 2 (Mtrf2), DRP, and OPA1, which regulate mitochondrial fusion/fission, were unchanged between groups [32]. Overall, these differences were concomitant changes observed in mitochondrial sizehape and basal respiration, and point towards perturbations in mitochondrial homeostasis induced by BH4 deficiency. Moreover, proteins associated with the control of bioenergetic function decreased in our BH4-deficient model, including those of the TCA cycle, such as Acyl-CoA synthetase, ATP-citrate synthase, isocitrate dehydrogenase, and fumarase—possibly reflecting altered control of bioenergetic flux at specific points in the pathway. Finally, certain subunits of electron transport chain proteins were upregulated in BH4-deficient cells, including NADH-ubisemione oxidoreductase chain 1 and 2 (complex I) and ATP synthase F(0) complex subunit B1 (complex V), indicating BH4 deficiency induced alterations in electron transport capacity. In total, these results show a striking change in the proteome of cells deficient of BH4 and highlight an overall change in mitochondrial dynamics, bioenergetics, and redox signalling.

In summary, this study shows increased mitochondrial O$_2^-$ in vitro models of BH4 deficiency, therefore providing strong evidence of an eNOS-independent role for BH4 in mitochondrial redox signalling. BH4 is a redox-active molecule and oxidation to BH2 plays a significant part in the decreased bioavailability observed in disease states. In accordance with previous reports [22–24], we have detected biopterins in mitochondria. We also evidence lower levels of BH4 in the mitochondria of BH4-depleted cells and show that, of the remaining, a greater proportion is oxidised. It is therefore plausible that BH4 is having a direct effect inside mitochondria, leading to increased O$_2^-$.

Mitochondria are known critical sources and targets of ROS, under both physiological and pathophysiological conditions [21,22] and elucidating the role of BH4 is of vital importance. Enzymatic cofactor-independent roles of BH4 so far remain relatively unexplored, although a direct cofactor role in the mitochondria has previously been alluded to [24,33]. The overlap of the interconnecting themes of BH4 altered redox signalling and mitochondrial bioenergetic metabolism present an opportunity to explore this concept further (Fig. 7). BH4 has been shown to act as a scavenger of ROS in vitro [34]; however, this study shows effects of BH4 deficiency that suggest a more profound role for BH4 in the mitochondrial homeostasis. It is interesting to note that GTPCH acts directly on guanosine triphosphate (GTP), a product of the TCA cycle, which we have shown to be perturbed by BH4 deficiency. It has been shown that GTP is a regulator of BH4 synthesis and it would be interesting to investigate the effect of BH4/GTPCH deficiency on GTP production and TCA activity [35]. Indeed, perturbed TCA cycle activity, and GTP production may underlie the increase in succinate observed in the current study.

Redox imbalance, oxidative stress, and decreased NO and BH4 are well-established markers of endothelial dysfunction in vascular pathol-
4.2. Gch1 knockdown by RNA interference

Geneticin® maintained in medium containing Hygromycin B (200 μg/ml). NIH 3T3 murine fibroblasts stably transfected with a tet-O transactivator construct. In the presence of doxycycline, binding of the transactivator is blocked, and gene expression is prevented. These initial 3T3-tet-off cells, previously shown to express neither eNOS nor GTPCH and also confirmed to be devoid of neuronal NOS, inducible NOS, and eNOS protein, were stably transfected with a plasmid encoding hemagglutinin (HA) antigen-tagged-human GCH1 under the control of a tetracycline-responsive element, individual colonies were isolated and analysed for GCH1 expression and a cell line, termed “GCH cells,” was established from expansion of a single colony. GCH cells were stably transfected with a plasmid encoding a human eNOS-eGFP fusion protein and clones were picked. All of the cell lines underwent three rounds of clonal selection. GCH cells were maintained in medium containing Hygromycin B (200 μg/ml) and Genetin® (200 μg/ml). NIH 3T3 murine fibroblasts were stably transfected with a Tet-Off transactivator construct, as previously described. Doxycycline (1 μg/ml) was added to cell culture media to abolish transcription of Gch1 mRNA where appropriate as previously described [19].

4.2. Gch1-specific knockdown by RNA interference

Gch1-specific, ON-TARGETplus SMARTpool siRNA were purchased from Dharmacon Thermo Scientific. The siRNA were used as a pool of four specific siRNA duplexes with the following sequences: Duplex 1, GGUAGAAGCUAGAAGCU; Duplex 2, CGAAGAUGUGCCUAAGUA; Duplex 3, GAGAGGAGAAUGCCUUU; and Duplex 4, AGUAGUGAUAGAGCAGA. 24 h prior to transfection, sEnd.1 cells were seeded into 6-well plates. Cells were then transfected with negative control siRNA (100 nmol/litre), using DharmaFect1 transfection reagent (Dharmacon). Cells were cultured for 72 h and gene silencing was detected by analysis of GTPCH protein expression by means of Western blotting using GTPCH-specific antibodies.

4.3. Bioterin quantification by HPLC with electrochemical detection

BH4, BH3, and bioterin levels in cell and mitochondrial lysates were determined by HPLC followed by electrochemical and fluorescent detection, as described previously [36,37]. Briefly, the cells were grown to confluency and harvested by trypsinisation. Mitochondria from confluent T175 flasks were isolated using the Qproteome Mitochondrial Isolation Kit (Qiagen). Sample pellets were resuspended in PBS (50 mmol/litre), pH 7.4, containing diithioerythritol (1 mmol/litre) and EDTA (100 μmol/litre) and subjected to three freeze-thaw cycles. Following centrifugation (15 min at 17,000g, 4 °C), the samples were transferred to new, cooled microtubes and precipitated with ice-cold extraction buffer containing phosphoric acid (1 mol/litre), trifluoroacetic acid (2 mol/litre), and diithioerythritol (1 mmol/litre). The samples were vigorously mixed and then centrifuged for 15 min at 17,000g, 4 °C. The samples were injected onto an isocratic HPLC system and quantified using sequential electrochemical (Coulonelm III, ESA Inc.) and fluorescence (Jasco) detection. HPLC separation was performed using a 250 mm, ACE C-18 column (Hichrom) and mobile phase comprising of sodium acetate (50 mmol/litre), citric acid (5 mmol/litre), EDTA (48 μmol/litre), and diithioerythritol (160 μmol/litre) (pH 5.2) (all ultrapure electrochemical HPLC grade), at a flow rate of 1.3 ml/min. Background currents of +500 μA and −50 μA were used for the detection of BH4 on electrochemical cells E1 and E2, respectively. 7,8-BH2 and bioterin were measured using a Jasco FP2020 fluorescence detector. Quantification of BH4, BH3, and bioterin was made by comparison with authentic external standards and normalised to sample protein content.

4.4. Quantification of superoxide production by HPLC

Measurement of 2-hydroxyethylidium formation by HPLC was used to quantify O2− production, from methods adapted from those described previously [38,39]. Cells grown in 6-well plates at 70–80% confluency were incubated in the presence or absence of L-NAME (200 μmol/litre), rotenone (2 μmol/litre), apocynin (100 μmol/litre), TTFA (5 μmol/litre), oxyypurinol (100 μmol/litre), and sepiapterin (10 μmol/litre). After 30 min, dihydroethidium (25 μmol/litre) was added and the cells were then incubated for a further 20 min, at 37 °C. Cells were then harvested by scraping and centrifuged, before being lysed in ice-cold methanol. Hydrochloric acid (100 mmol/litre) was added (1:1 v/v) prior to loading into the autosampler for analysis. All samples were stored in darkened tubes and protected from light at all times. Separation of dihydroethidium, 2-hydroxyethylidium, and ethidium was performed using a gradient HPLC system (Jasco) with an ODS3 reverse phase column (250 mm, 4.5 mm; Hichrom) and quantified using a fluorescence detector set at 510 nm (excitation) and 595 nm (emission). A linear gradient was applied from Mobile phase A (0.1% trifluoroacetic acid) to Mobile phase B (0.085% trifluoroacetic acid in acetonitrile), over 23 min (30–50% acetonitrile).

4.5. Imaging mitochondrial superoxide production

Cells grown on confocal dishes were washed once in Krebs-HEPES buffer, incubated with MitoTracker Green (Thermo Fisher Scientific), before exposure to MitoSOX™ Red (Thermo Fisher Scientific) for 20 min at 37 °C. Hoechst nuclear stain was added 5 min before imaging with a Zeiss 510 Metathead confocal microscope, using excitation and emission wavelengths of 488 nm and 595 nm, respectively.

4.6. Mitochondria isolation

Cells grown to confluence in T175 flasks were harvested by trypsinisation and pelleted at 400g, at 4 °C. Mitochondria were isolated using the Qproteome Mitochondria Isolation Kit (Qiagen), as per the manufacturer’s instructions. All steps were carried out on ice or at 4 °C and mitochondrial pellets were stored at −80 °C for BH4, Western, or proteomic analysis.

4.7. Western blotting

Cell or mitochondrial lysates were prepared by homogenisation in ice-cold Celllyte™ M buffer (Sigma) containing protease inhibitor cocktail (Roche Applied Science). Lysates were centrifuged at 17,000g for 10 min at 4 °C, and samples were prepared using LDS sample buffer (Invitrogen). Western blotting was carried out using standard techniques with anti-GAPDH, -VDAC, -cytochrome C, -SDH, -GTPCH, -TXNIP, -GR, -FH, -TRX, -PDH, -TOM20, -COXIV, -Mitofusin 2, -OPA1, DRP1, p(ser616)DRP1, p(ser637)DRP1 and β-tubulin antibodies.
4.8. Proteomics

Mitochondrial pellets were dissolved in 6 M urea in 50 mM ammonium bicarbonate. Dithiothreitol (10 mM) was added and samples were incubated at 60 °C for 45 min. Samples were diluted 1:10 in 50 mM ammonium bicarbonate and sequencing grade modified trypsin (Promega) was added (1:50 w/w) for overnight digestion. PMSF (0.5 mM) stopped the reaction and samples were dried down in a vacuum concentrator (Speedvac, Thermo Scientific) and resuspended in acetonitrile (2%) and TFA (0.1%). Samples were desalted using ZipTip C18 pipette tips (Millipore), vacuum concentrated and reconstituted in acetonitrile (2%) and TFA (0.1%), before mass spectrometric analysis. LC-MS/MS was performed using a Q Exactive mass spectrometer, coupled with a Dionex Ultimate 3000 UPLC. Samples underwent online desalting using a Trap column (PepMAP C18, 300 μm×5 mm, 5 μm particle, Thermo). Subsequently, a nEASY column (PepMAP C18, 75 μm×500 mm, 2 μm particle, Thermo) was used with a flow rate of 250 nl/min over 60 min and a gradient of 2–35% acetonitrile in 5% DMSO/0.1% Formic acid to achieve UPLC separation.

Survey scans were acquired with a resolution of 70,000 at 200 m/z and an ion target of 3E6 between 380 and 1800 m/z for up to 100 ms. MS/MS spectra were acquired with a resolution of 17,500 and an ion target of 1E5 for up to 128 ms and a fixed first mass of 100 m/z and normalised collision energy of 28. Selected precursors were picked above a threshold of 4.7E7 counts and excluded for 27 s. Experiments were conducted in biological triplicates and all sample analysed in a single sample batch.

4.9. Proteomic data analysis

For label free quantitation raw data were imported into Progenesis QI (Waters) with default settings. MS2 spectra were identified with Mascot v 2.5 (Matrix Science) by searching Uniprot/Swissprot (retrieved 12/08/2014) with taxonomy Mus musculus, using 10 ppm and 0.05 Da peptide mass/fragment mass tolerances. Allowance was made for 1 missed cleavage site. Carbamidomethylation (C) was selected as fixed modification and Deamidation (N/Q) and Oxidation (M) as variable modifications. Data was exported for integration in Progenesis with a peptides false discovery rate of 1%. Furthermore, spectra with a peptide score < 20 were discarded. Peptide abundances were mean normalised to identified features only.

4.10. Metabolomics

Metabolite extraction: sEnd.1 endothelial cells transfected with Gch1-specific siRNA were compared to cells transfected with NS scrambled control siRNA. Briefly, 200ul of 80% ice-cold, aqueous MeOH was added to the cell pellet containing approximately 1 million (pre-counted) frozen cells. The cell pellet was disrupted through aspiration to obtain a cell suspension in 80% MeOH. The cell suspension was then clarified by centrifugation at 14,800 rpm for 20 min at 4 °C. The supernatant was removed and placed in an autosampler vial and kept at −80 °C. On the day of analysis, the extract was allowed to warm to 4 °C in the chilled autosampler and then injected directly onto the system.

Metabolite analyses were performed using a Thermo Scientific ICS-5000+ ion chromatography system coupled directly to a Q-Exactive HF Hybrid Quadrupole-Orbitrap mass spectrometer with a HESI II electrospray ionisation source (Thermo Scientific, San Jose, CA). The ICS-5000+ HPLC system incorporated an electrolytic anion generator (KOH) programmed to produce an OH− gradient over 37 min. An inline electrolytic suppressor removed the OH− ions and cations from the post-column eluent prior to MS analysis (Thermo Scientific Dionex AERS 500). A 10 μL partial loop injection was used for all analyses and the separation was performed using a Thermo Scientific Dionex IonPac AS11-HC 2×250 mm, 4 μm particle size column with a Dionex Ionpac AG11-HC 4 μm 2×50 guard column inline. The IC flow rate was 0.250 ml/min. The total run time was 37 min and the hydroxide ion gradient comprised as follows: 0 mins, 0 mM; 1 min, 0 mM; 15 mins, 60 mM; 25 mins, 100 mM; 30 mins, 100 mM; 30.1 mins, 0 mM; 37 mins, 0 mM. Analysis was performed in negative ion mode using ascan range from 80 to 900 and resolution set to 70,000. The tune file source parameters were set as follows: sheath gas flow 60; aux gas flow 20; spray voltage 3.6; capillary temperature 320; S-lens RF value 70; heater temperature 450. AGC target was set to 1E6 and the Max IT value was 250 ms. The column temperature was kept at 30 °C throughout the experiment. Full scan data were acquired in continuum mode. Peaks retention times were identified from the injection of authentic standards and peaks from unknown samples were identified using a combination of accurate mass analysis (< 2 ppm) and retention time using Thermo Scientific Quanbroker software (Thermo Fisher Scientific, Hemmel, UK).

4.11. Seahorse XF96 OCR analysis

48–72 h post siRNA transfection, sEnd.1 cells were plated at a density of 7.5×10^4 cells per well into XF96 microplates. Cells were left to attach for 24 h before extracellular flux analysis. One hour prior to the assay, cells were washed and the culture medium was replaced with XF assay medium (modified DMEM, pH 7.4; Seahorse Bioscience), supplemented with glucose (25 mM/l), glutamine (2 mM/l), and pyruvate (2 mM/l), before being incubated at 37 °C, at atmospheric CO2 levels. Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) were measured using the XF96 analyser (Seahorse Bioscience). Basal OCR measurements were taken followed by injection of the following compounds from the XF Cell Mito Stress Test Kit (Seahorse Bioscience): oligomycin (1 μmol/l, injection port A), FCCP (1 μmol/l, injection port B), and combined antimycin A (0.5 μmol/l) and rotenone (0.5 μmol/l) (injection port C). All data were normalised to protein concentration, measured via BCA assay.

4.12. Transmission electron microscopy and mitochondrial measurements

Cells were grown and transfected on plastic coverslips. 72 h post-transfection, cells were washed in PBS, and fixed in warm glutaraldehyde (2.5%), PFA (2%), and PIPES buffer (0.1 M, pH7.2) for 30 min at room temperature. Secondary fixation was carried out for 1 h at 4 °C in osmium tetroxide (1%) in PIPES buffer (0.1 M, pH 7.2), followed by tertiary fixation in uranyl acetate (0.5%) over night at 4 °C. Samples were embedded in resin after ethanol dehydration and gradual infiltration with Agar100 epoxy resin. After heat polymerisation, samples were sectioned (90 nm) using the Leica UC7 ultramicrotome with a diamond knife and post stained with Reynolds' lead citrate. 5–7 cells per sample were imaged using a FEI Tecnai 12 Transmission Electron Microscope (TEM) at 120 kV, using a Gatan US1000 digital CCD camera. Mitochondria were randomized, counted ‘blinded’ to the user, and the length (by placing a tip-to-tip line across the longest axis of each mitochondrion), and area (by drawing around and selecting each individual mitochondrion) quantified using scale bars and ImagePro Plus 6 (Media Cybernetics) [40,41].

4.13. Mitochondrial DNA content

Mitochondrial DNA relative to nuclear DNA was assessed using real-time PCR and a Bio-Rad CFX96 detection system and iTaq Universal SYBR Green Supermix. DNA was extracted from cell pellets using the Qiagen DNeasy Blood and Tissue kit following the manufacturers protocol. Primers specific to nuclear DNA genes were Actin (Actb Forward-CTG CCTGAGCCAGGGCAAG, Rev-GAAAAGGCGCTCAGGGCA) and Succinate dehydrogenase complex subunit A (Sdha Forward-TACTACAC CCCCAAAGCT, Rev-TGGGACCAGCTTCTTATGC). Primers for mitochondrial DNA genes were cytchrome B (mtCytb Forward-
CCACCTCATTACCTTTATAGGC, Rev- TTTATATCGATCTGAGT TTAATCTG) and subunit II of mitochondrial cytochrome C oxidase (mtCO2 Fwd-CTACAAGACGCCAT, Rev- GAGAGGGAGAGCAAT). In each reaction mixture 2 ng of DNA was used.

4.14 Statistical analysis

Data are expressed as mean ± SEM. Comparisons between NS and GCH siRNA were made by the unpaired Student's t-test. Experiments testing multiple treatments between cell type and knockdown were compared by two-way ANOVA, with post-hoc tests applied to test for significance between knockdown and treatments, as outlined in the figure legends. P < 0.05 was considered statistically significant.

Author contributions

JB, AS, RF, BJR, MJC: Carried out experiments and analysed data. BMK, JM, RWM: Provided technical assistance, data interpretation and reviewed the manuscript. KMC and MJ: Concept of the ideas, interpreted the data. JB, AS and MJ: Wrote the manuscript. No conflicts of interest.

Acknowledgements

This work was supported by British Heart Foundation Intermediate Fellowship awarded to MJC (FS/14/56/31049), a British Heart Foundation Programme Grant (RG/12/5/29576), Wellcome Trust (090532/Z/09/Z), and the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre. The authors also acknowledge support from the BHF Centre of Research Excellence, Oxford (RE/ 13/1/30181).

Appendix A. Supplementary material

Supplementary data associated with this article can be found in the online version at doi:10.1016/j.freeradbiomed.2017.01.012.

References

[1] N.S. Kwon, C.F. Nathan, D.J. Stuehr, Reduced biotin as a cofactor in the generation of nitrogen oxides by marine macrophages, J. Biol. Chem. 264 (1989) 20496–20501.
[2] M.A. Tayeh, M.A. Marletta, Macropage oxidation of L-arginine to nitric oxide, nitrite, and nitrate. Tetrahydrobiopterin is required as a cofactor, J. Biol. Chem. 264 (1989) 19654–19658.
[3] E. Stroes, M. Hijmering, M. van Zandvoort, R. Wever, T.J. Rabelink, E.E. van Faassen, Origin of superoxide production by endothelial nitric oxide synthase, FERS Lett. 438 (1998) 161–164.
[4] J. Vasquez-Vivar, B. Kalyanaraman, P. Martasek, N. Hogg, B.S. Masters, H. Karouli, P. Tordi, K.A. Pritchard Jr., Superoxide formation by endothelial nitric oxide synthase: the influence of cofactors, Proc. Natl. Acad. Sci. USA 95 (1998) 9220–9225.
[5] N. Kuzkaya, N. Weissmann, D.G. Harrison, S. Dilavolak, Interactions of peroxynitrite, tetrahydrobiopterin, ascorbic acid, and thiols: implications for uncoupling endothelial nitric-oxide synthase, J. Biol. Chem. 278 (2003) 22546–22554.
[6] S. Midtien, Z. Ratuski, Oxidation of tetrahydrobiopterin by peroxynitrite: implications for vascular endothelial function, Biochem. Biophys. Res. Commun. 263 (1999) 681–684.
[7] C. Antoniades, C. Shirodaria, N. Warrick, S. Cai, J. de Bono, J. Lee, P. Leeson, E. McNeill, M.J. Crabtree, A.B. Hale, K.M. Channon, Integrated redox sensor and effector functions for tetrahydrobiopterin- and glutathionylation-dependent endothelial nitric-oxide synthase uncoupling, J. Biol. Chem. 288 (2013) 561–569.
[8] J.K. Bendall, G. Douglas, E. McNeill, K. Channon, M.J. Crabtree, A.J. Robinson, L.M. Work, C. Frezza, T. Krieg, M.P. Murphy, Ischaemic accumulation of succinate and biopterin redox status: Insights from cells with tet-regulated GTP cyclohydro-lase I expression, J. Biol. Chem. 284 (2009) 1136–1144.
[9] A. Daiber, Redox signaling (cross-talk) from NO to mitochondria involves mitochondrial pores and reactive oxygen species, Bba-Bioenerg. 1797 (2010) 899–906.
[10] S. Sethumadhavan, J. Whitsett, B.A. Bennett, L.A. Ionoana, G.M. Pieper, J. Vasquez- Vivar, Increasing tetrahydrobiopterin in cardiomyocytes adversely affects cardiac red state and mitochondrial function independently of changes in NO production, Free Radic. Biol. Med. 93 (2016) 1–11.
[11] J. Du, R.J. Teng, M. Lawrence, R. Xu, Y. Shi, The protein partners of ETF and G6PD, J. Biol. Chem. 281 (2006) 9222–9225.
[12] N.J. Alp, S. Mussa, J. Khoo, T.J. Guzik, S. Cai, A. Jefferson, K.A. Rockett, K.M. Channon, Tetrahydrobiopterin-dependent preservation of nitric oxide-mediated endothelial function in diabetes by targeted transgenic GTP-cychohydro-lase I overexpression, J. Clin. Investig. 112 (2003) 725–735.
[13] N.J. Alp, M.A. McTeer, J. Khoo, R.P. Choudhury, K.M. Channon, Increased endothelial tetrahydrobiopterin synthesis by targeted transgenic GTP-cychohydro-lase I overexpression reduces endothelial dysfunction and atherosclerosis in ApoE knockout mice, Arterioscler. Thromb. Vasc. Biol. 24 (2004) 445–450.
[14] S. Cai, J. Khoo, K.M. Channon, Augmented BIH4 by gene transfer restores nitric oxide synthase function in hyperglycemic human endothelial cells, Cardiovasc. Res. 65 (2005) 822–831.
[15] S. Wang, J. Xu, P. Song, Y. Wu, J. Zhang, H. Chul Choi, M.-H. Zou, Acute inhibition of guanosine triphosphate cytochrome d1 uncouples endothelial nitric oxide synthase and elevates blood pressure, Hypertension 52 (2008) 484–490.
[16] F. Liu, P. Storz, Reactive oxygen species in cancer, Free Radic. Res. 44 (2010) 479–496.
[17] O. Hwang, Role of oxidative stress in Parkinson’s disease, Exp. Neurobiol. 22 (2013) 11–17.
[18] K. Starumara, J.F. Keaneey Jr., Reactive oxygen species in cardiovascular disease, Free Radic. Biol. Med. 51 (2011) 978–982.
[19] J. Vasquez-Vivar, B. Kalyanaraman, P. Martasek, The role of tetrahydrobiopterin in superoxide generation from eNOS: enzymology and physiological implications, Free Radic. Res. 37 (2003) 121–127.
[20] M.J. Crabtree, A.L. Tatham, Y. Al-Wakeel, N. Warrick, A.B. Hale, S. Cai, K.M. Channon, N.J. Alp, Quantitative regulation of intracellular endothelial nitric oxide synthase (eNOS) coupling by both tetrahydrobiopterin-eNOS stoichiometry and biotin in redox status: Insights from cells with tet regulated GTP cychohydro-lase I expression, J. Biol. Chem. 284 (2009) 1136–1144.
[21] A. Daiber, Redox signaling (cross-talk) from NO to mitochondria involves mitochondrial pores and reactive oxygen species, Bba-Bioenerg. 1797 (2010) 899–906.
[22] N.J. Alp, M.A. McAteer, J. Khoo, R.P. Choudhury, K.M. Channon, Increased endothelial tetrahydrobiopterin synthesis by targeted transgenic GTP-cychohydro-lase I overexpression reduces endothelial dysfunction and atherosclerosis in ApoE knockout mice, Arterioscler. Thromb. Vasc. Biol. 24 (2004) 445–450.
[23] A.P. Fernandes, A. Holmgren, Glutaredoxins: glutathione-dependent redox enzymes with functions far beyond a simple thioredoxin backup system, Antioxid. Redox Signal. 19 (2013) 1539–1605.
[24] A.P. Fernandes, A. Holmgren, Glutaredoxins: glutathione-dependent redox enzymes with functions far beyond a simple thioredoxin backup system, Antioxid. Redox Signal. 6 (2004) 63–74.
[25] C.M. Koehler, K.N. Beverly, E.P. Leverich, Redox pathways of the mitochondrion, Antioxid. Redox Signal. 8 (2006) 813–822.
[26] S. Sethumadhavan, J. Whitsett, B.A. Bennett, L.A. Ionoana, G.M. Pieper, J. Vasquez- Vivar, Increasing tetrahydrobiopterin in cardiomyocytes adversely affects cardiac red state and mitochondrial function independently of changes in NO production, Free Radic. Biol. Med. 93 (2016) 1–11.
[27] J.B. Bailey et al. Appendix A. Supplementary material

This work was supported by British Heart Foundation Intermediate Fellowship awarded to MJC (FS/14/56/31049), a British Heart Foundation Programme Grant (RG/12/5/29576), Wellcome Trust (090532/Z/09/Z), and the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre. The authors also acknowledge support from the BHF Centre of Research Excellence, Oxford (RE/ 13/1/30181).
[37] S. Heales, K. Hyland, Determination of quinonoid dihydrobiopterin by high-performance liquid chromatography and electrochemical detection, J. Chromatogr. 494 (1989) 77–85.

[38] H. Zhao, J. Joseph, H.M. Fales, E.A. Sokoloski, R.L. Levine, J. Vasquez-Vivar, B. Kalyanaraman, Detection and characterization of the product of hydroethidine and intracellular superoxide by HPLC and limitations of fluorescence, Proc. Natl. Acad. Sci. USA 102 (2005) 5727–5732.

[39] B. Fink, K. Laude, L. McCann, A. Doughan, D.G. Harrison, S. Dikalov, Detection of intracellular superoxide formation in endothelial cells and intact tissues using dihydroethidium and an HPLC-based assay, Am. J. Physiol. Cell Physiol. 287 (2004) C895–C902.

[40] N.K. Khoo, L. Mo, S. Zharikov, C. Kamga-Pride, K. Quesnelle, F. Golin-Bisello, L. Li, Y. Wang, S. Shiva, Nitrite augments glucose uptake in adipocytes through the protein kinase A-dependent stimulation of mitochondrial fusion, Free Radic. Biol. Med. 70 (2014) 45–53.

[41] D.B. Wang, G.A. Garden, C. Kinoshita, C. Wyles, N. Babazadeh, B. Sopher, Y. Kinoshita, R.S. Morrison, Declines in Drp1 and parkin expression underlie DNA damage-induced changes in mitochondrial length and neuronal death, J. Neurosci. 33 (2013) 1357–1365.